$Invesco QQQ Trust(QQQ)$ $SPDR S&P 500 ETF Trust(SPY)$ $NVIDIA Corp(NVDA)$ $Meta Platforms, Inc.(META)$  Top investors are not confident on the latest bullish trend!The investor behind a major global ETF told CNBC recently that she sees a bearish pattern in the Big Tech rally.  While on CNBC's "ETF Edge" last week, Anna Paglia, the managing director and global head of ETFs and indexed strategies at Invesco QQQ Trust said investors are beginning to play defense when it comes to the group.“If you look at the flows that are flattish

newbie still  observing

If its Volalite market where you predict that prices might move ,but not sure direction[Smug]  Choose growth stock[Bless]  Identify the possible price levels you might want it to go up or down [Silence]  Buy equal shorts and puts [Smart]  Exit when prices are adequate for your p and l expectations[Serious]  Never forget about transaction or other fees

need to look into all the factors before I trade as to ensure the growth is favorable to me. 

Since the last financial report, $Walt Disney(DIS)$ stock price has been fluctuating due to market observation of the effects of its leadership change in streaming media. Therefore, there was little volatility before the release of Q2 FY23 earnings on May 10th. However, it seems that the announcement of the financial report has set a general pattern for the entire streaming media industry.Although it fell by 4% after hours, it only erased gains from previous days.FY23Q2 Earnings OverviewOverall, current performance met expectations.Revenue was $21.815 billion, up 13.3% YoY and in line with market expectations;Non-GAAP operating profit was $3.285 billion, down 11.2% YoY but slightly higher than market expectations of $3.175 billion;Adjusted EPS was

Tiger is a good platform for us to learn about trading and the interface is friendly

Earnings of growth stocks diverge greatly in this earnings season.$Snap Inc(SNAP)$ shares dropped as much as 20%; $Cloudflare, Inc.(NET)$ plunged as much as 25% in after-hours trading Thursday; $Lyft, Inc.(LYFT)$ dropped 17%; $Upstart Holdings, Inc.(UPST)$ surged 50% yesterday.The roller-coaster ride of growth stocks happens every day in this earnings season.How to profit from their divergence and wild ride?Straddle helps you profit from high volitilityStraddle refers to buying a combination of “call and put” with the same strike price and expiration date, with the strike price usually taken close to the current price (AT

$Roblox Corporation(RBLX)$ is due to release its first-quarter earnings results before the market opens on this Wednesday. It is a popular online gaming platform targeting young children, and was listed on 10 March 2021 when its share price rallied to close at 69.50, a hefty 54% above its IPO price of $45. I had jumped onto the bandwagon after noticing the popularity of the platform among kids including my children who would spend hours playing games on it whenever time permits. Roblox is among pioneers in the development of gaming experiences in the metaverse that is the emerging digital frontier that has attracted investments from the likes of $Meta Platforms, Inc.(META)$ 

SummaryI argue that Affirm's outlook for the next quarter will not positively surprise investors.Affirm's business model is far from reaching self-sustainability, meaning that it's far from being a profitable enterprise.Affirm's business model has come home to roost.Business And Media Elites Attend Annual Allen & Co Meetings In Sun ValleyInvestment ThesisAffirm (NASDAQ:AFRM) is about to report its Q3 2023 results next Tuesday, after-hours. I argue that investors are not too late to give this investment a miss or even to sell out of their holdings.There's a confluence of factors weighing on Affirm's near-term prospects. Not only are credit markets tightening, which will lead to Affirm not succeeding in rolling off the credit from its balance sheet, but contemporaneously, the Buy Now Pay

Options Market Statistics: Traders Purchase Large Volume of Calls on Alphabet $Tesla Motors(TSLA)$ shares down 1.54%, with option volume of 1.08 million, and calls accounted for 53.5%. The 170.00 calls expiring Friday lead the flow with a volume of 113,417. Tesla broke ground Monday on its new lithium refinery in Texas, which is expected to produce enough of the battery-grade metal to build 1 million electric vehicles by 2025. $Alphabet(GOOG)$  shares down 0.39%, with option volume of 0.44 million, and calls accounted for 71.5%. The 110.00 calls expiring Friday lead the flow with a volume of 57,106. The New York Times is getting around $10

Find out how one beaten-down company and one highflier both gained ground.The stock market had a tough day on Tuesday, losing ground as investors awaited key inflation data that should come out on Wednesday. The worst drop came for the Nasdaq Composite (^IXIC), with less extreme declines for the Dow Jones Industrial Average (^DJI -0.17%) and S&P 500 (^GSPC -0.46%).There are still many stocks that are far below their best levels in recent years after 2022's bear market, while others have found ways to perform well even under tough conditions.$Upstart Holdings, Inc.(UPST)$ (UPST 5.31%) and $Celsius Holdings, Inc.(CELH)$ (CELH 0.21%) both reported their latest financial results after the closing bell on

$Mullen Automotive(MULN)$  Global EV sales for year 2022 is around 10 million units (up ~60% vs 6.5 million units in year 2021). The global EV sales is expected to grow to ~13.6 million units in year 2023 (which presents a growth of ~30% yoy). However, the competition among different EV brands is getting more intense and the price war to obtain more market share is hurting the profit margin for most EV car makers. One must admit that the competition in the EV market has intensified as numerous traditional car markers (Mercedes-Benz, BMW etc) are also investing and building more EV units. Surprisely, Mullen has yet to deliver any car but it claims big orders for its vans to be delivered in 2024. Sounds like a risky in

As for the core assets of large consumer categories, such as liquor, known as A-shares, may be the reason I don't drink alcohol myself; I only pay some attention to these sectors. For large consumers, emerging industries with low penetration rates are the focus of my attention. As a result, I began to pay attention to the transplant industry last year. Yonghe is a Hong Kong-listed company that I had been watching until now, a leader in the hair transplant industry. I often see people ask, is a hair transplant medical or cosmetic? Why is everyone asking that? Because hair transplantation is actually a medical aesthetic minimally traumatic surgery, it is necessary to go to a regular, professional institution to perform it. Just in time for the end of the year 2022, Yonghe Medical's first com

In addition to the outperforming $Meta Platforms, Inc.(META)$ and $Tesla Motors(TSLA)$ at the beginning of the year, stocks of small companies are leading the market’s monthlong rally. More and more investors are coming to believe that the end of interest-rate hikes is just around the corner.Don't miss the trend1) $Carvana Co.(CVNA)$ - another meme stock is brewingCarvana, an e-commerce platform for buying and selling used cars in US, has rose 207.78% in 2023.Carvana has been recently sought after by retail investors, as the market's bearish bets on the sto

$Catalyst Biosciences(CBIO)$  $PolarityTE, Inc.(PTE)$  $Inspira Technologies Oxy B.H.N. Ltd.(IINN)$  Health Care Select Sector SPDR Fund (XLV) was slipping 0.1%. The iShares Biotechnology ETF (IBB) was sinking 1.8%. In company news, Catalyst Biosciences (CBIO) rose 3.3% after the biopharmaceutical company said it acquired global rights to F351, a phase 3 drug candidate to treat liver and kidney fibrosis as part of a reverse merger with GNI Group, a publicly traded company in Tokyo and the majority owner of Beijing Continent, the Chinese drug maker that developed F351. Catalyst plans to issue common and preferred stock that will eventually provide GN

$Fennec Pharmaceuticals Inc.(FENC)$  $Jazz Pharmaceuticals PLC(JAZZ)$  Introduction ​In late September, Fennec Pharmaceuticals (NASDAQ:FENC) announced it had received FDA-approval for Pedmark. This came after two FDA rejections related to manufacturing deficiencies. Fennec has spent over a decade getting Pedmark to market, resulting in an accumulated deficit of nearly $200 million. The company now shifts its attention towards Pedmark's arrival to the market. Children undergoing cisplatin-based chemotherapy, used in the treatment for many pediatric cancers, often succumb to ototoxicity, or hearing loss. Not only is this costly (e.g. hearing aids, cochlear implants), it is associated with decline